Nestor 8-K 2009
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2009
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
42 Oriental Street; Third Floor, Providence, Rhode Island
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On January 9, the Board of Directors of Nestor, Inc. (the “Company”) notified Clarence A. Davis, Chief Executive Officer of its decision to terminate his employment contract with the Company, effective immediately. Mr. Davis will retain his position as a Class III Director of the Company.
On January 13, 2009, the Board of Directors appointed Michael C. James, currently serving as Chairman of the Board, as Chief Executive Officer of the Company, effective immediately. Mr. James currently serves as Chairman of Company’s Audit and Compensation Committees and has been the Managing Partner of Kuekenhof Capital Management, LLC, a private investment management company, since 1999. Mr. James also holds the position of Managing Director of Kuekenhof Equity Fund, L.P. and Kuekenhof Partners, L.P. Mr. James is a director of Guided Therapeutics, Inc. where he is Chairman of the Compensation Committee and serves on the Audit Committee.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.